Evotec and Ohio State to Collaborate on Novel Cancer Therapy
December 22 2014 - 1:42AM
- Collaboration leverages the breadth & experience of
Evotec's drug discovery infrastructure
- Efforts will explore the use of a novel approach,
discovered at Ohio State, for targeting mutant KRas
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today
announced a research collaboration with the laboratories of Prof.
Roger Briesewitz at The Ohio State University Comprehensive Cancer
Center – Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute ("OSUCCC – James").
The objective of the collaboration is to progress a novel
mechanism for engaging the KRas target discovered at The Ohio State
University using Evotec's technology platform and broad expertise
in drug discovery and pre-clinical development, thereby validating
and progressing novel leads into pharmaceutically developable
candidates.
KRas is a small GTPase regulating the RAS/MAPK signalling
cascade that governs cell division. Mutations in KRas are early
transforming events in tumourigenesis and are highly prevalent in
lethal cancers such as lung, colon and pancreatic cancer.
Addressing the challenging tractability of this well-established
oncology target, work conducted at Ohio State provides a novel
route to engage the target.
"Working and initiating a strategic dialogue with OSUCCC is a
great privilege for us, especially in such an important field in
oncology. Activating mutations of KRas are one of the most frequent
genetic events in cancers, and yet mutant KRas has long been
considered an intractable drug target. However, working with Roger
and his team, we believe we have an opportunity to attack this
elusive target from a different angle with the potential to deliver
an exciting new anti-cancer therapeutic", said Dr Werner
Lanthaler, Chief Executive Officer of Evotec.
"Through this collaboration with Evotec, novel biological
discoveries and medical insights made at Ohio State will be
effectively translated into a state-of-the-art drug discovery
project. The collaboration is already demonstrating the benefit of
an alliance in accelerating drug discovery projects", said
Dr Tim Wright, Founding Partner and Director Drug Development
Institute OSU Comprehensive Cancer Center James Cancer Hospital
& Solove Research Institute, Vice President, Technology
Commercialization Office.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. Evotec has long-term discovery alliances with partners
including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition,
the Company has existing development partnerships and product
candidates both in clinical and pre-clinical development. These
include partnerships with Boehringer Ingelheim and MedImmune in the
field of diabetes, with Janssen Pharmaceuticals in the field of
depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
ABOUT THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER
CENTER – ARTHUR G. JAMES CANCER HOSPITAL AND RICHARD J. SOLOVE
RESEARCH INSTITUTE
Ohio State's Comprehensive Cancer Center – Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute ("OSUCCC –
James") strives to create a cancer-free world by integrating
molecular- and genetic-based discoveries into patient care, a
strategy that leads to better prevention, detection and treatment
of individual cancers. OSUCCC – James is one of only 41 National
Cancer Institute-designated Comprehensive Cancer Centers and one of
only four centers funded by the NCI to conduct both phase I and
phase II clinical trials. More than 300 cancer researchers from 12
of Ohio State's 14 colleges collaborate across research programs
and disciplines to make some of the world's most game-changing
discoveries. In December 2014, The Ohio State University will open
the doors of the new James Cancer Hospital and Solove Research
Institute, a transformational facility that fosters collaboration
and integration of cancer research and clinical cancer care. The
new James will help revolutionize cancer prevention and care by
enabling world-class oncologists and researchers to work
side-by-side to solve the mysteries of this disease.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: For further information, please contact
Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Apr 2023 to Apr 2024